[{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Entrectinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thermo Fisher Scientific \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Thermo Fisher Scientific \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Entrectinib","moa":"TRK\/ROS1\/ALK\/JAK2\/TNK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Entrectinib","moa":"TRK\/ROS1\/ALK\/JAK2\/TNK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Entrectinib","moa":"TRK\/ROS1\/ALK\/JAK2\/TNK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Entrectinib","moa":"TRK\/ROS1\/ALK\/JAK2\/TNK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Entrectinib","moa":"TRK\/ROS1\/ALK\/JAK2\/TNK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Entrectinib","moa":"TRK\/ROS1\/ALK\/JAK2\/TNK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Entrectinib","moa":"TRK\/ROS1\/ALK\/JAK2\/TNK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pellet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Entrectinib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive CNS tumors in pediatric patients.

                          Product Name : Rozlytrek

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 20, 2023

                          Lead Product(s) : Entrectinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.

                          Product Name : Rozlytrek

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 05, 2023

                          Lead Product(s) : Entrectinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.

                          Product Name : Rozlytrek

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 02, 2023

                          Lead Product(s) : Entrectinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.

                          Product Name : Rozlytrek

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 01, 2022

                          Lead Product(s) : Entrectinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Approval by the MHLW would accelerate access to Chugai's targeted therapy via a locally administered, next-generation sequencing (NGS) biomarker test.

                          Product Name : Rozlytrek

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 07, 2020

                          Lead Product(s) : Entrectinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Chugai Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.

                          Product Name : Rozlytrek

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 16, 2020

                          Lead Product(s) : Entrectinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive brain metatases.

                          Product Name : Rozlytrek

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 28, 2020

                          Lead Product(s) : Entrectinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          BIO Asia-Taiwan
                          Not Confirmed
                          BIO Asia-Taiwan
                          Not Confirmed

                          Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.

                          Product Name : Rozlytrek

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 21, 2020

                          Lead Product(s) : Entrectinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank